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doi:10.1016/j.ejvs.2010.11.005Abstract Objective: To evaluate and compare changes over time in health-related quality of
life reported by patients with small (4.1e5.4 cm) abdominal aortic aneurysms (AAAs) under-
going endovascular aortic aneurysm repair (EVAR) or surveillance.
Methods: Participants were randomly assigned to receive either early EVAR or surveillance
within a multicentre, randomised clinical trial on small AAA (Comparison of surveillance vs.
Aortic Endografting for Small Aneurysm Repair, CAESAR). Patient-reported health-related
quality of life was assessed before randomisation, at 6 months and yearly thereafter using
the Short Form 36 (SF-36) Health Survey.
Results: Between 2004 and 2008, 360 patients (345 males, mean age 68.9 years) were rando-
mised, 182 to early EVAR and 178 to surveillance. There was one perioperative death. Mean
follow-up was 31.8 months. No significant difference in survival was found. At baseline, compa-
rable quality of life scores were recorded in both treatment groups: Total SF-36: 73.0 versus
75.5 (p Z 0.18), Physical domain: 71.4 versus 73.3 (p Z 0.33); Mental health domain: 70.9
versus 72.7 (p Z 0.33), in the EVAR arm versus the surveillance arm, respectively. Six months
after randomisation, Total SF-36 and Physical and Mental domain scores were all significantly
higher with respect to baseline in the EVAR group, while patients of the surveillance group
scored lower. The differences between EVAR and surveillance arms in score changes at 6
months were significant and in favour of EVAR: Total score: difference 5.4; p Z 0.0017; Phys-
ical: difference 3.8; p Z 0.02; and Mental: difference 6.0; p Z 0.0005. Differences between
EVAR and surveillance diminished over time. At the last assessment, patients in both groups
had decreased scores with a significant drop with respect to the baseline (3.9 in EVAR,the 2010 Annual ESVS Vascular Meeting, held in Amsterdam, 16e19 September 2010.
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Quality of Life in CAESAR Trial 3256.3 in surveillance). There were no significant differences between the EVAR and surveillance
arms: Total score: p Z 0.25; Physical: p Z 0.47; and Mental: p Z 0.38.
Conclusions: Patients with small AAA under surveillance compared with early EVAR had signif-
icant impaired functional health at 6 months after assignment. After a mean of 31.8 months,
SF-36 health-related quality of life in patients allocated to early EVAR and surveillance was
similar.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The lack of evidence supporting the strong superiority of
one of the available treatment strategies (surveillance,
open surgery and endovascular repair), the awareness of
having a small abdominal aortic aneurysm (AAA) that shows
no negligible risk of enlargement and need for repair in the
next few years might be of great concern for the affected
patient. Different management strategies for patients with
small symptomless AAA provide similar survival rates and
can variably and heavily impact public health and patients’
perceived quality of life (QoL). Observation without repair
requires close patient surveillance with suitable imaging,
appropriate medical therapy and long-term follow-up.
Early open repair is associated with higher early (operative)
risks while early endovascular aortic aneurysm repair
(EVAR) shows decreased operative risk but requires long-
term follow-up and secondary interventions. It is not clear
which of these strategies has a heavier impact on QoL, and,
therefore, can better influence the choice of the best
strategy for the treatment of small AAA. Although studies
measuring patient-perceived QoL after open repair re-
vealed stable or even improved scores after the post-
operative period,1e3 when other studies measured QoL
after EVAR,3e5 the results are not consistent.
The Comparison of surveillance vs. Aortic Endografting
for Small Aneurysm Repair (CAESAR) trial is a randomised
trial designed to determine the mortality risks, complica-
tion rates, aneurysm enlargement rates and health-related
QoL after early EVAR repair compared with periodic
computed tomography (CT) and ultrasound surveillance of
aneurysms with 4.1e5.4-cm diameter. CAESAR recently
reported6 that 54-month mortality rates were similar in the
two groups: 14.5% in EVAR and 10.1% in the surveillance
group (pZ 0.6). Although survival was the primary trial end
point, other important consequences of the trial included
the impact of these policies on the patients’ perception of
how their QoL was influenced by the knowledge of having
a life-threatening disorder being followed-up over time or
their relief after an endovascular procedure that might
decrease the likelihood of dying from a ruptured aneurysm
but requiring long-term follow-up. This was integrated as
a secondary end point of the trial and measured using
a validated measurement tool, the Short-Form 36-item (SF-
36) questionnaire.
This study compared the change over time in patient-
perceived QoL up to 54 months after early EVAR and
surveillance in the CAESAR population.
Methods
The methods of the CAESAR trial have been reported previ-
ously.7 Patients with AAA of 4.1e5.4 cm were randomlyassigned, in a 1:1 ratio, to receive immediate EVAR or
surveillancebyultrasoundþCTand repair onlyafter adefined
threshold (diameter 5.5 cm, enlargement >1 cm /year and
symptoms) achievement. Patients were informed about the
random allocation to early EVAR or surveillance (with poten-
tial delayed treatment during follow-up) and written consent
was required. The main end point was all-cause mortality.
Recruitment is closed.
The trial was performed according to the CONSORT
Statement recommendations and registered at http://www.
clinicaltrials.gov with NCT Identifier: NCT00118573 (Study ID
Numbers ICMJE 384/03).
The study was approved by a central human rights
committee and the institutional review boards at each
participating centre.
Between August 2004 and December 2008, 345 male
(95.8%) patients and 15 females (4.2%), aged 50e79 years
with mean aneurysm diameter 47.22 mm (SD 3.24) were
enrolled (early EVAR Z 182; surveillance Z 178).
Health-related QoL was measured using the standardised
SF-36,8 a validated multi-item questionnaire that measures
general physical functioning, social functioning, role func-
tioning, bodily pain, general mental health, vitality and
general health perception. The questionnaire consists of 36
questions evaluating eight different health dimensions
(domains) of QoL:
Physical Function (PF): limitations in physical activities
because of health problems; Social Function (SF): limita-
tions in social activities because of physical or emotional
problems; Role-Physical (RP): limitations in role activities
because of physical health problems; Bodily Pain (BP);
Mental Health (MH): physiological distress and well-being;
General Health (GH): general health perception; Vitality
(VT): energy and fatigue; and Role Emotional (RE): limita-
tions in usual role activities because of emotional prob-
lems. Two summary component (aggregated) measures, the
physical health component score (PHS) and mental health
component score (MHS) are derived from the eight SF-36
domains and reported. The PHS reflects physical morbidity
and aetiology, and the MHS reflects physiologic or mental
morbidity and aetiology. Data from the questionnaires were
transformed using a conversion table and entered into
software provided by Quality Metrics. Norm-based (raw)
scores for the eight SF-36 domains were obtained. For each
domain, a raw score was then transformed to a 0e100 scale
(transformed scores) with 0 representing worst health and
100 optimal functioning (best health scale).
The SF-36 questionnaire was administered by the clini-
cian and self-compiled by patients at the time of enrolment
(before patients were aware of the random allocated
treatment) and every 6 months during follow-up.
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Analysis of QoL was by intention to treat.
The QoL data are presented as mean  standard devia-
tion (SD). For the purpose of comparison between groups, t-
test and the analysis of variance were used. Homogeneity
(equality) of population variances was assessed with Lev-
ine’s test. Differences in scores are expressed as the mean
difference with 95% confidence intervals (CIs). Mean and SD
scores were calculated in both randomisation arms (EVAR
and surveillance) and compared. Changes over the time
were analysed for each arm considering three time points:
baseline, intermediate (after 6 months) and at last follow-
up available (after 1 year or more). At each time point,
mean scores for the eight SF-36 domains were compared.
Changes in time in QoL were also calculated within the
same randomisation arm relative to the baseline level.
Adjusted comparisons for age (more than or less than 70
years) and for patients receiving late repair in the surveil-
lance arm were performed. A value of p < 0.05 was
considered statistically significant.
Statistical analyses were performed using Bio-Medical
Data Package (BMDP) version 2009 Statistical Software Inc.
(Los Angeles, CA, USA). SF-36 data were analysed using
software provided by Quality Metrics.
Results
There were no differences in baseline characteristics
(demographic, morphology and SVS risk factors) between
EVAR and surveillance groups. Mean follow-up was
31.8  17.4 months: 31.8  16.9 in the early EVAR group
and 31.7  18.0 in the surveillance arm.
Of the 182 patients randomly assigned to early EVAR,
six declined treatment and one underwent open repair
by patient’s choice. In three other patients, immediate
conversion to open surgery was required due to EVAR
failure.
Of the 178 aneurysms under surveillance, 85 were
repaired during follow-up: 71 by EVAR and 14 by open repair
due to EVAR suitability loss.Table 1 Baseline SF-36 assessment.
Total EVA
Mean score SD Mea
Total score 73
Physical health
Physical Health summary scale 72.3 17.7 71.4
Physical functioning (PF) 76.3 21.3 75.4
Role-physical (RP) 77 35.5 75.6
Bodily pain (BP) 81.4 22.6 78.5
General health (GH) 59.85 20.4 60.6
Mental health
Mental Health summary scale 71.8 18 70.9
Vitality (VT) 67.9 20.4 67.8
Social functioning (SF) 80.6 22 78.1
Role emotional (RE) 80.3 34.4 78.2
Mental health (MH) 70.1 19 69.5
Data in bold is the 3 summary scores that include all the following sAneurysm-related mortality was similar in the two groups
with one death occurring in each. Overall, two late ruptures
occurred (both in the surveillance group). The 54-month
cumulative probability of all-cause mortality was 14.5% in
early EVAR and 10.1% in the surveillance group (p Z 0.6).
Major adverse events (in 11 patients) were equally
distributed in the two groups. Ten re-interventions were
needed after early EVAR repair and none in the surveillance
group (p Z 0.033). No migration or loss of graft integrity
occurred.
The preoperative questionnaire response rate was 95%
(173/182) in the early EVAR group and 93% (166/178) in the
surveillance group (p Z 0.50). Six-month assessment was
performed at a mean of 7.0  1.9 months from baseline
(7.3  1.5 months in the EVAR group and 6.8  1.7 in the
surveillance group). Last assessment was performed at
a mean of 36.3  14.7 months (36.5  13.3 months in the
EVAR group and 36.2  15.9 in the surveillance group) from
baseline. Six-month questionnaires were available for 140
patients in the early EVAR group and 148 in the surveil-
lance group. Questionnaires for last assessment (1 year or
more) were available from 132 EVAR and 133 surveillance
patients.
No significant difference was noted in preoperative
baseline total mean SF-36 scores between the two groups
(73.0  17.9 EVAR vs. 75.5  16.2 surveillance, p Z 0.18).
Similarly, there were no baseline differences in mean PHS
score (71.4  18.1 EVAR vs. 73.3  17.4 surveillance,
p Z 0.33) and mean MHS score (70.9  18.9 EVAR vs.
72.7  17.0 surveillance, pZ 0.33) between the two groups
(Table 1). However, analysing individual domains, patients
under surveillance scored higher in BP (mean: 78.5  23.9
EVAR vs. 84.4  20.8 surveillance, p Z 0.015) and SF
(mean: 78.1  22.6 EVAR vs. 83.3  21.1 surveillance,
p Z 0.03).
The changes of the domains of SF-36 over time for each
trial arm are shown in Figs. 1e3 and Tables 1e4.
At 6-month evaluation, mean SF-36 total scores
decreased in the surveillance (74.6  16.9) patients and
increased in the EVAR (78.4  16.2) patients. Compared
with baseline, the difference within the surveillance armR (N Z 173) Surveillance (N Z 166) P- value
n score SD Mean score SD
17.9 75.5 16.2 0.1869
18.1 73.3 17.4 0.3353
22.4 77.2 20.1 0.4386
36.1 78.5 35 0.4556
23.9 84.4 20.8 0.0152
20.7 59.1 20.3 0.5013
18.9 72.7 17 0.3395
20.7 68.1 20.3 0.8933
22.6 83.3 21.1 0.0302
35.9 82.5 32.8 0.2498
19.3 70.6 18.8 0.6193
pecific single scores detailed in the rows below.
Figure 1 Total score in EVAR and surveillance patients.
Quality of Life in CAESAR Trial 327(delta 0.8; p Z 0.51) was not significant, whereas
patients within the early EVAR arm showed a significant
increase in the mean total score (delta 4.6; p Z 0.0002).
The changes in mean SF-36 scores at 6 months from
baseline were significantly higher for early EVAR patients
than for surveillance patients (delta from baseline EVAR vs.
surveillance: 5.4; pZ 0.0017). The significant difference in
changes from baseline was evident in both mean summary
PHS score (delta EVAR vs. surveillance 3.8; p Z 0.024;
Fig. 2) and mean summary MHS score (delta EVAR vs.
surveillance 6.0; p Z 0.0005; Fig. 3).
Within individual domains of the SF-36 (Figs. 1e3 and
Tables 2e4), a significant 6-month drop occurred in three
(all Physical domains) of the eight domains for the surveil-
lance patients (PF, RP and BP). A significant 6-monthFigure 2 Physical Health component score in EVAR and surveillan
GH: General Health.improvement was detected in four of the individual domains
for the early EVAR patients, one Physical (GH) and three
Mental domains (SF, RE and MH).
At last assessment (1 year or more after randomisation),
both EVAR and surveillance groups similarly decreased in
scores to reach mean total score levels lower than baseline:
70.0  19.2 in the early EVAR and 69.3  20.0 in the
surveillance group. The 1-year drop in total mean SF-36
score compared with baseline was significant in both early
EVAR (delta 3.9; pZ 0.009) and surveillance (delta 6.3;
p  0.0001) patients. Significant 1-year drop was also
evident either for mean PHS or for mean MHS scores (Tables
2e4). Changes in individual domains are shown in Figs. 1e3
and Tables 2e4. Both early EVAR and surveillance groups of
patients scored significantly lower than baseline in physicalce. PF: Physical Functioning; RP: Role-Physical; BP: Bodily Pain;
Figure 3 Mental Health component score in EVAR and surveillance. VT: Vitality; SF: Social Functioning; RE: Role Emotional; MH:
Mental Health.
328 P. De Rango et al.functioning and vitality. In the domains of general health,
role emotional and mental health, no significant drop
occurred in the mean SF-36 score at1 year in either group.
In the domains of role-physical, bodily pain and social func-
tioning, there was significant drop in surveillance patients,
while the drop was not significant in early EVAR patients.
Adjusted analyses
Effect of late repair in the surveillance arm. Because 85
patients under surveillance received delayed repair, we
repeated the analysis of the SF-36 data where these subset
of patients were separately analysed. Total mean SF-36
scores were 76.1  16.8 at baseline, 74.0  18.3 at 6
months and 70.1  19.9 at last assessment. This adjusted





Total score 4.6 2.3 to 7
Physical health
Physical Health summary scale 3.1 0.8 to 5.5
Physical functioning (PF) 0.6 3.7 to 2.4
Role-physical (RP) 0.2 5.7 to 5.3
Bodily pain (BP) 2 5.6 to 1.6
General health (GH) 4.4 1.3 to 7.4
Mental health
Mental Health summary scale 5.2 2.8 to 7.5
Vitality (VT) 0.1 2.9 to 3.2
Social functioning (SF) 7.5 3.9 to 11.1
Role emotional (RE) 9.1 2.1 to 16.0
Mental health (MH) 4.8 1.7 to 7.8
Data in bold is the 3 summary scores that include all the following s6 months and 1 year. Changes in score with respect to
baseline and to the randomisation arm (EVAR vs. surveil-
lance) were similar to those found in the main analysis at
the same times.
Ageatrandomisation.Analysisofage-adjustedSF-36 scores
showed that in both EVAR and surveillance arms patients 70
years had significantly lower mean scores than younger
patients in the physical functioning (p Z 0.0001) domain at
baseline. This age-adjusted analysis did not significantly
change the SF-36 overall outcomes at 6 months and 1 year.
Discussion
Given the lack of evidence supporting any superiority in
survival for repair versus surveillance in small AAA
management, the individualisation of treatment choices12 months
P value Mean difference
from baseline
95% CI P- value
0.0002 L3.9 L6.9 to -1.0 0.0093
0.0094 L5.8 L8.7 to -2.9 <0.0001
0.6755 11.5 15.3 to 7.7 0.0001
0.9406 6.1 12.7 to 0.4 0.0677
0.2733 0.3 4.1 to 4.7 0.8992
0.0055 3.3 6.7 to 0.1 0.0603
<0.0001 L2.8 L5.9 to 0.3 0.0763
0.9449 8.3 11.7 to 5.0 <0.0001
0.0001 1.3 5.6 to 3.0 0.5424
0.0115 0.5 6.9 to 8.0 0.8928
0.0024 1.4 4.8 to 2.0 0.4078
pecific single scores detailed in the rows below.
Table 3 Changes in quality of life over time in surveillance.
6 months 12 months
Mean difference
from baseline
95% CI P value Mean difference
from baseline
95% CI P- value
Total score L0.8 L3.2 to 1.6 0.5132 L6.3 L9.3 to -3.4 <0.0001
Physical health
Physical Health summary scale L0.7 L3.1 to 1.7 0.5545 L7.3 L10.1 to -4.4 <0.0001
Physical functioning (PF) 4.3 7.3 to 1.2 0.0059 8.2 12.0 to 4.4 <0.0001
Role-physical (RP) 7.4 12.9 to 1.8 0.0093 8.5 15.0 to 1.9 0.0115
Bodily pain (BP) 10.7 14.3 to 7.1 <0.0001 10 14.4 to 5.7 <0.0001
General health (GH) 0.6 2.4 to 3.7 0.6932 2.7 6.1 to 0.7 0.1183
Mental health
Mental Health summary scale L0.8 L3.2 to 1.5 0.4853 L4.8 L7.9 to -1.7 0.0027
Vitality (VT) 2.4 5.4 to 0.7 0.1280 0.7 10.4 to 3.7 <0.0001
Social functioning (SF) 0.4 3.2 to 4.0 0.8179 7.2 11.5 to 2.9 0.0010
Role emotional (RE) 3.2 10.2 to 3.8 0.3756 3.8 11.2 to 3.7 0.3222
Mental health (MH) 0.3 2.7 to 3.4 0.8353 3.2 6.6 to 0.2 0.0689
Data in bold is the 3 summary scores that include all the following specific single scores detailed in the rows below.
Quality of Life in CAESAR Trial 329might be appropriate. However, the risk-issue benefit is
complex and should be discussed with patients: patient
satisfaction and costs of treatment might weigh heavily
when deciding which treatment is the best during routine
clinical practice. Concerns about the short-term and long-
term outcomes after detecting a small AAA pose the
question as to whether patients’ perception of well-being
would change if they would undergo sequential observation
rather than early endovascular repair of a potentially life-
threatening disorder. In both treatment choices, long-term
follow-up/observation is required, the difference being
before or after the repair. The most rigorous way of
addressing these issues is with a randomised controlled trial
(RCT) designed to obtain unbiased information about the
balance of risks, benefits and costs.
Data fromarandomised trial comparingQoLafterEVARand
surveillance in large AAA have not demonstrated consistent
differences in scores between the two groups in high-risk
patients.5 This might be because of the poor baseline scores
due to the high-risk population and the less-perceived benefitTable 4 Changes in quality of life from baseline in EVAR vs sur




Total score 5.4 2.1 to 8.8
Physical health
Physical Health summary scale 3.8 0.5 to 7.2
Physical functioning (PF) 3.6 0.7 to 7.9
Role-physical (RP) 7.1 0.7 to 15.0
Bodily pain (BP) 8.7 3.6 to 13.7
General health (GH) 3.7 0.6 to 8.1
Mental health
Mental Health summary scale 6.0 2.7 to 9.3
Vitality (VT) 2.5 1.8 to 6.8
Social functioning (SF) 7.1 2.0 to 12.2
Role emotional (RE) 12.2 2.3 to 22.1
Mental health (MH) 4.4 0.1 to 8.8
Data in bold is the 3 summary scores that include all the following sfrom whichever treatment is used in such patients. To our
knowledge, CAESAR is the first randomised study on QoL after
EVAR and surveillance in small AAA at low surgical risk.
Longitudinal analysis of CAESAR data revealed that, in
low-risk patients, both EVAR and surveillance have an effect
on QoL; however, early repair by EVAR seems to have a small
but positively significant impact on current health percep-
tion, particularly in the first 6 months after a small AAA
detection. Indeed, in the surveillance arm, a small but
perceptible deterioration on almost all domains either
physical (delta from baseline: PF 4.3; RP 7.4; BP 10.7;
and GH: 0.6) or mental (delta from baseline: VT 2.4; SF:
0.4; RE: 3.2; and MH: 0.3) was detected at 6 months. On
the contrary, patients reported significant improvement in
perceived global mental (p  0.0001) and physical
(p Z 0.0094) health in the first 6 months after EVAR. This
was also particularly evident in Mental health domains (SF
(delta score 7.5; p Z 0.0001), RE (delta score: 9.1;
pZ 0.011), and MH (delta score 4.8; pZ 0.002)) and in GH
(delta score 4.4; pZ 0.005) perception. After 6 months, theveillance patients at 6 month and at late assessment.
ce 12 months EVAR vs Surveillance
p value Mean score
change
95% CI p-value
0.0017 2.4 L1.7 to 6.6 0.2525
0.0241 1.5 L2.6 to 5.5 0.4792
0.0968 3.3 8.7 to 2.0 0.2240
0.0730 2.4 6.9 to 11.6 0.6183
0.0009 10.3 4.1 to 16.5 0.0011
0.0903 0.6 5.4 to 4.3 0.8218
0.0005 2.0 L2.4 to 6.4 0.3808
0.2602 1.3 6.0 to 3.4 0.5921
0.0067 5.9 0.2 to 12.0 0.0574
0.0158 4.3 6.3 to 14.8 0.4264
0.0446 1.7 3.1 to 6.5 0.4822
pecific single scores detailed in the rows below.
330 P. De Rango et al.perceived health similarly deteriorated in the EVAR and
surveillance arms to score lower than baseline. Although
one would not expect patients to feel physically better after
no treatment with respect to recovery from a procedure,
the higher SF-36 scores in the EVAR patients at 6 months
with respect to surveillance could be explained by a general
feeling of physical or psychological well-being after survival
and recovery from treatment of a potentially life-threat-
ening condition. However, the awareness of an unresolved
problem (untreated small AAA) and the uncertainty of the
need for repair might negatively alter health perception in
patients under surveillance. Nevertheless, after the early
benefit perception, the continuous need for instrumental
follow-up inside a rigid protocol of a prospective study, the
possibility of re-intervention and failure of the endograft,
together with the increasing age in an elderly population
might adversely affect patient QoL in early EVAR as
compared with those in the surveillance group. Indeed, QoL
scores of CAESAR patients continued to decrease after 6
months, reaching significantly lower than baseline scores in
both trial arms. However, the 1-year health perception
remained non-significantly better after EVAR than after
surveillance (score difference with respect to baseline:
3.9 in EVAR vs. 6.3 in surveillance). These results cannot
be explained by differences in intensity of surveillance as
follow-up protocols for EVAR and surveillance were the
same. It could be that patients under surveillance in the
long-term scored lower than patients under EVAR because of
a persisting major adverse perception of lack of treatment.
Nevertheless, our results should be interpreted with
caution: despite the statistical relevance, the effect size of
QoL score differences might not allow for a large clinical
value in healthy patients with small AAA. Measurements in
QoL are difficult to state objectively, and a number of
instruments examining variable items and tools of health
perception with different sensitivity have been used. While
the changes in QoL we found were partially comparable to
those of other trials in patients with AAA,1e4 other studies
analysing the impact of more invasive interventions in
vascular patients showed more consistent score changes in
QoL,9,10 such as the Bypass versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial after bypass graft versus
angioplasty in patients with severe critical limb ischaemia.
Nevertheless, despite larger changes, the gain in QoL
perception in BASIL patients with bypass grafts was not
cost-effective.9
In our study, analysis of costs associated with treatment
has not yet been performed. Therefore, the short-term
small benefit for early EVAR in QoL shown in the CAESAR trial
cannot be used as the basis of change of treatment practice
while further studies should address cost-effectiveness and
health economic evaluation of EVAR in small aneurysms.
Interestingly, the requirement of delayed treatment did
not change health perception in our patients under
surveillance. When we separately analysed SF-36 scores in
patients requiring repair after surveillance (regardless of
EVAR or open surgery), the results were similar to those of
the whole surveillance group. However, our findings cannot
be applied to QoL perception in aneurysms after open
surgery, as only a small percentage of our patients received
this treatment. From RCTs, it seems that the perceived QoL
in patients with AAA might be superior after open repairthan after surveillance1 or after EVAR;3 but there is no
consensus in this regard.2,4 The UK trial found that 12
months after randomisation to receive early open surgery
or surveillance, early surgery patients reported more posi-
tive SF-36 score improvement (of approximately six points)
in current perception of health-related QoL and less nega-
tive change in bodily pain.1 The DREAM trial comparing
EVAR versus open repair in patients with large AAA (using
both the SF-36 and the Euro-QoL instruments) found that at
6 months and beyond, surgical patients reported better
quality-of-life perception with a significantly higher Euro-
QoL score after surgery than after EVAR (p Z 0.001),
despite the reduced invasiveness of EVAR.3 The explanation
by the authors was that people might experience a rela-
tively better health perception after a period of severe
illness or major surgery. Other non-randomised and rando-
mised studies using SF-36 or different QoL measurements
failed to find significant differences in scores in the late
postoperative period between EVAR and open repair.
Negligible differences in QoL between the EVAR group
versus the open surgery group were demonstrated in the
EVAR 1 after 12 months,4 and in the Open Versus Endovas-
cular Repair (OVER) trial after 2 years.2 Differently from
these trials, our results were based on a single instrument
evaluation (SF-36) to encourage patients’ response rate. In
particular, we did not use the Euro-QoL, often used in
major European trials. Both the SF-36 and the Euro-QoL are
shown to provide valid measurements of health status;
however, SF-36 appears to be more sensitive to differences
in health for people with less severe morbidity and seems
less affected by the ‘ceiling’ effect (inability to distinguish
variation in patients’ satisfaction because most people are
highly satisfied with their personal care).11 As only transient
changes were detected among eight dimensions of SF-36,
we would not expect major difference in score by using
additional generic instruments broadly exploring similar
domains as the Euro-QoL (based on five dimensions).
The SF-36 health survey is one of the most commonly
used surveys in RCTs on aneurysms,1e5 and one of the most
valuable instruments to measure patient-perceived QoL
and well-being before and after treatment12e14 with
demonstrated high validity, reliability and psychometric
property.14,15 The SF-36 has been validated for patients
with vascular diseases,9,10,12,16 and its use in the surgical
populations has been promoted by the American College of
Surgeons and the American Society of Vascular Surgery.15,16
This study has some limitations. Different protocols for
surveillance or aneurysm repair could influence patient
health perception. The strict schedule and severity of
follow-up surveillance (requiring annual CT and not only
ultrasound) for both surveillance and EVAR arms in the
CAESAR study might have negatively affected the perceived
health benefit of patients, especially in the surveillance
arm. In addition, the study lacks cost analysis. The rather
intense follow-up schedule, as well as the absence of
a precise analysis of costs associated with treatment limits
the generalisation of our data.
The relatively small sample size and the low number of
adverse events, despite the well-balanced patient ran-
domisation, might have introduced potential for bias
in recognising a difference between treatment groups
(underpowered).
Quality of Life in CAESAR Trial 331Furthermore, the absence of a precise reference pop-
ulation (aged matched) for comparison with our cohort of
patients constrains our data. Nevertheless, our QoL mean
scores were comparable to those reported in other studies
on SF-36 in healthy patients with AAA.1,3 Accuracy in
patients’ response and consistency of response are other
limitations inherent to any QoL study.
Conclusions
Our data support the fact that early small AAA repair with
EVAR can have a short-lasting positive impact on current
health perception but the perception returns lower than
baseline after 6 months. Both the options of surveillance or
early EVAR do not alter the tendency to a slow decline with
time in patients’ QoL that is not affected by patient age at
baseline or delayed treatment. These data on overall well-
being, in addition to benefits and risks, can be used to help
inform patients in the decisional planning when a small AAA
is detected in routine clinical practice.
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